These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1042 related items for PubMed ID: 31735691

  • 1. T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study.
    Conte B, Fabi A, Poggio F, Blondeaux E, Dellepiane C, D'Alonzo A, Buono G, Arpino G, Magri V, Naso G, Presti D, Mura S, Fontana A, Cognetti F, Molinelli C, Pastorino S, Bighin C, Miglietta L, Boccardo F, Lambertini M, Del Mastro L, Gruppo Italiano Mammella (GIM) study group.
    Clin Breast Cancer; 2020 Apr; 20(2):e181-e187. PubMed ID: 31735691
    [Abstract] [Full Text] [Related]

  • 2. Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer.
    Migeotte A, Dufour V, van Maanen A, Berliere M, Canon JL, Taylor D, Duhoux FP.
    BMC Cancer; 2021 Nov 11; 21(1):1204. PubMed ID: 34763656
    [Abstract] [Full Text] [Related]

  • 3. Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab.
    Al Rabadi LS, Cook MM, Kaempf AJ, Saraceni MM, Savin MA, Mitri ZI.
    BMC Cancer; 2021 Oct 27; 21(1):1150. PubMed ID: 34706686
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort.
    Moinard-Butot F, Saint-Martin C, Pflumio C, Carton M, Jacot W, Cottu PH, Diéras V, Dalenc F, Goncalves A, Debled M, Patsouris A, Mouret-Reynier MA, Vanlemmens L, Leheurteur M, Emile G, Ferrero JM, Desmoulins I, Uwer L, Eymard JC, Cheaib B, Courtinard C, Bachelot T, Chevrot M, Petit T.
    Breast; 2022 Jun 27; 63():54-60. PubMed ID: 35299035
    [Abstract] [Full Text] [Related]

  • 5. T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study.
    Schettini F, Conte B, Buono G, De Placido P, Parola S, Griguolo G, Fabi A, Bighin C, Riccardi F, Cianniello D, De Laurentiis M, Puglisi F, Pelizzari G, Bonotto M, Russo S, Frassoldati A, Pazzola A, Montemurro F, Lambertini M, Guarneri V, Cognetti F, Locci M, Generali D, Conte P, De Placido S, Giuliano M, Arpino G, Del Mastro L.
    ESMO Open; 2021 Apr 27; 6(2):100099. PubMed ID: 33819752
    [Abstract] [Full Text] [Related]

  • 6. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.
    Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot X, Burris H, Petersen JA, Stanzel S, Strasak A, Patre M, Ellis P.
    J Clin Oncol; 2017 Jan 10; 35(2):141-148. PubMed ID: 28056202
    [Abstract] [Full Text] [Related]

  • 7. Combining Endocrine Therapy with Trastuzumab Emtansine Improves Progression-Free Survival and Overall Survival in HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer.
    Kınıkoğlu O, Odabas H, Altıntaş YE, Yıldız A, Çakan B, Akdağ G, Yıldırım S, Bal H, Kaya T, Tünbekici S, Işık D, Başoğlu T, Yıldırım ME, Turan N.
    Medicina (Kaunas); 2024 Jun 07; 60(6):. PubMed ID: 38929568
    [Abstract] [Full Text] [Related]

  • 8. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study.
    Bon G, Pizzuti L, Laquintana V, Loria R, Porru M, Marchiò C, Krasniqi E, Barba M, Maugeri-Saccà M, Gamucci T, Berardi R, Livi L, Ficorella C, Natoli C, Cortesi E, Generali D, La Verde N, Cassano A, Bria E, Moscetti L, Michelotti A, Adamo V, Zamagni C, Tonini G, Barchiesi G, Mazzotta M, Marinelli D, Tomao S, Marchetti P, Valerio MR, Mirabelli R, Russo A, Fabbri MA, D'Ostilio N, Veltri E, Corsi D, Garrone O, Paris I, Sarobba G, Giotta F, Garufi C, Cazzaniga M, Del Medico P, Roselli M, Sanguineti G, Sperduti I, Sapino A, De Maria R, Leonetti C, Di Leo A, Ciliberto G, Falcioni R, Vici P.
    J Exp Clin Cancer Res; 2020 Dec 10; 39(1):279. PubMed ID: 33302999
    [Abstract] [Full Text] [Related]

  • 9. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE.
    Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P, Martin M, Pienkowski T, Pivot XB, Burris HA, Petersen JA, De Haas S, Hoersch S, Patre M, Ellis PA.
    Cancer; 2019 Nov 15; 125(22):3974-3984. PubMed ID: 31318460
    [Abstract] [Full Text] [Related]

  • 10. Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B).
    Yokoe T, Kurozumi S, Nozawa K, Ozaki Y, Maeda T, Yazaki S, Onishi M, Fujimoto A, Nakayama S, Tsuboguchi Y, Iwasa T, Sakai H, Ogata M, Terada M, Nishimura M, Onoe T, Masuda J, Kurikawa M, Isaka H, Hagio K, Shimomura A, Okumura Y, Futamura M, Shimokawa M, Takano T.
    Breast Cancer; 2021 May 15; 28(3):581-591. PubMed ID: 33389616
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis.
    DeBusk K, Abeysinghe S, Vickers A, Nangia A, Bell J, Ike C, Forero-Torres A, Blahna MT.
    Future Oncol; 2021 Nov 15; 17(33):4635-4647. PubMed ID: 34463120
    [Abstract] [Full Text] [Related]

  • 12. Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Huober J, Weder P, Ribi K, Thürlimann B, Thery JC, Li Q, Vanlemmens L, Guiu S, Brain E, Grenier J, Dalenc F, Levy C, Savoye AM, Müller A, Membrez-Antonioli V, Gérard MA, Lemonnier J, Hawle H, Dietrich D, Boven E, Bonnefoi H, Swiss Group for Clinical Cancer Research, Unicancer Breast Group, and Dutch Breast Cancer Research Group.
    JAMA Oncol; 2023 Oct 01; 9(10):1381-1389. PubMed ID: 37561451
    [Abstract] [Full Text] [Related]

  • 13. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
    Perez EA, de Haas SL, Eiermann W, Barrios CH, Toi M, Im YH, Conte PF, Martin M, Pienkowski T, Pivot XB, Burris HA, Stanzel S, Patre M, Ellis PA.
    BMC Cancer; 2019 May 30; 19(1):517. PubMed ID: 31146717
    [Abstract] [Full Text] [Related]

  • 14. Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.
    Krop IE, Im SA, Barrios C, Bonnefoi H, Gralow J, Toi M, Ellis PA, Gianni L, Swain SM, Im YH, De Laurentiis M, Nowecki Z, Huang CS, Fehrenbacher L, Ito Y, Shah J, Boulet T, Liu H, Macharia H, Trask P, Song C, Winer EP, Harbeck N.
    J Clin Oncol; 2022 Feb 10; 40(5):438-448. PubMed ID: 34890214
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experience.
    Battisti NML, Rogerson F, Lee K, Shepherd S, Mohammed K, Turner N, McGrath S, Okines A, Parton M, Johnston S, Allen M, Ring A.
    Cancer Treat Res Commun; 2020 Feb 10; 24():100188. PubMed ID: 32619830
    [Abstract] [Full Text] [Related]

  • 16. Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation.
    Yamashita-Kashima Y, Shu S, Osada M, Fujimura T, Yoshiura S, Harada N, Yoshimura Y.
    Cancer Chemother Pharmacol; 2020 Nov 10; 86(5):641-654. PubMed ID: 32997196
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population.
    Noda-Narita S, Shimomura A, Kawachi A, Sumiyoshi-Okuma H, Sudo K, Shimoi T, Noguchi E, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.
    Breast Cancer; 2019 Jul 10; 26(4):492-498. PubMed ID: 30737616
    [Abstract] [Full Text] [Related]

  • 18. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
    Martin M, Fumoleau P, Dewar JA, Albanell J, Limentani SA, Campone M, Chang JC, Patre M, Strasak A, de Haas SL, Xu J, Garcia-Saenz JA.
    Ann Oncol; 2016 Jul 10; 27(7):1249-56. PubMed ID: 27052654
    [Abstract] [Full Text] [Related]

  • 19. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
    Patel TA, Ensor JE, Creamer SL, Boone T, Rodriguez AA, Niravath PA, Darcourt JG, Meisel JL, Li X, Zhao J, Kuhn JG, Rosato RR, Qian W, Belcheva A, Schwartz MR, Kaklamani VG, Chang JC.
    Breast Cancer Res; 2019 Sep 02; 21(1):100. PubMed ID: 31477168
    [Abstract] [Full Text] [Related]

  • 20. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).
    Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, du Toit Y, Easton V, Lindegger N, Miles D, PERUSE investigators.
    Ann Oncol; 2019 May 01; 30(5):766-773. PubMed ID: 30796821
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.